Journal: Molecular Oncology

Article Title: Bile acids‐mediated overexpression of MUC4 via FAK‐dependent c‐Jun activation in pancreatic cancer

doi: 10.1016/j.molonc.2016.04.007

Figure Lengend Snippet: Activation of FXR is required for BA‐mediated MUC4 upregulation via Src/FAK/c‐Jun axis. A. Nuclear fraction obtained from 50 μM of DCA and CDCA treated CD18/HPAF cells, demonstrated increased levels of FXR compared to ...

Article Snippet: The primary antibodies used in the study are as follows: β‐Actin (Sigma, 1:5000), c‐Jun (SC‐1694, Santa Cruz Biotechnologies (SCB), 1:500), p‐c‐Jun (9261, Cell Signaling, 1:1000), c‐src (SC‐18, SCB, 1:500), p‐src (6943, Cell Signaling, 1:1000), FAK (SC‐558, SCB, 1:500), p‐FAK (8556, Cell Signaling, 1:1000), FXR (SC‐134481, SCB, 1:500) and MUC4 (In house generated, 1:1000).

Techniques: Activation Assay

Journal: Molecular Oncology

Article Title: Bile acids‐mediated overexpression of MUC4 via FAK‐dependent c‐Jun activation in pancreatic cancer

doi: 10.1016/j.molonc.2016.04.007

Figure Lengend Snippet: Clinical association between MUC4 and FXR in PC tissues. A. Expression profiling of FXR was performed in cDNA samples prepared from pancreatic tumor (n = 15) and tumor adjacent normal tissues (n = 4). Similar to its agonists, ...

Article Snippet: The primary antibodies used in the study are as follows: β‐Actin (Sigma, 1:5000), c‐Jun (SC‐1694, Santa Cruz Biotechnologies (SCB), 1:500), p‐c‐Jun (9261, Cell Signaling, 1:1000), c‐src (SC‐18, SCB, 1:500), p‐src (6943, Cell Signaling, 1:1000), FAK (SC‐558, SCB, 1:500), p‐FAK (8556, Cell Signaling, 1:1000), FXR (SC‐134481, SCB, 1:500) and MUC4 (In house generated, 1:1000).

Techniques: Expressing